Research Highlights: Highlights from the Latest Research in Cytochromes Pharmacogenomics

• Aithal G , DayCP, KestevenPJ, DalyAK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet353 , 717–719 (1999).
   PubMed Web of Science ®Google Scholar
• D‘Andrea G , D‘AmbrosioRL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105 , 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 , 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB et al.; The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125 , 1997–2005 (2012).
   PubMed Web of Science ®Google Scholar
• Shurin SB , NabelEG. Pharmacogenomics – ready for prime time? N. Engl. J. Med.358 , 1061–1063 (2008).
   PubMed Web of Science ®Google Scholar
• French B , JooJ, GellerNL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11 , 108 (2010).
   PubMed Web of Science ®Google Scholar
• Do EJ , LenziniP, EbyCS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5) , 417–424 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• European Pharmacogenetic Approach to Coumarin Anticoagulant Therapy (EU‑PACT). www.clinicaltrials.gov/ct2/show/NCT01119300 (Accessed 9January2013)
   Google Scholar
• Bristol–Meyers Squibb Company. Coumadin tablets (warfarin sodium tablets, USP) crystalline; Coumadin for injection (warfarin sodium for injection, USP). www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf (Accessed 7January2013)
   Google Scholar

• Pimenoff VN , LavalG, ComasD et al. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates. Pharmacogenet. Genomics 22(12) , 846–856 (2012).
   PubMed Web of Science ®Google Scholar
• Evans DM , CardonLR. A comparison of linkage disequilibrium patterns and estimated population recombination rates across multiple populations. Am. J. Hum. Genet.4 , 681–687 (2005).
   Google Scholar
• Peltonen L , PalotieA, LangeK. Use of population isolates for mapping complex traits. Nat. Rev. Genet.1 , 182–190 (2000).
   PubMed Web of Science ®Google Scholar
• Montpetit A , NelisM, LaflammeP et al. An evaluation of the performance of tag SNPs derived from HapMap in a Caucasian population. PLoS Genet. 2(3) , e27 (2006).
   PubMed Web of Science ®Google Scholar
• Teichert M , EijgelsheimM, RivadeneiraF et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18 , 3758–3768 (2009).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 , 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Cooper GM , JohnsonJA, LangaeeTY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112 , 1022–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Takeuchi F , McGinnisR, BourgeoisS et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3) , e1000433 (2009).
   PubMed Web of Science ®Google Scholar

▪ Website

• US FDA. Table of Pharmacogenomic Biomarkers in Drug Labels. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (Accessed 9January2013)
   Google Scholar

• He Y , HoskinsJM, McLeodHL. Copy number variants in pharmacogenetic genes. Trends Mol. Med.17(5) , 244–251 (2011).
   PubMed Web of Science ®Google Scholar
• Martis S , MeiH, VijzelaarR et al. Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J. doi:10.1038/tpj.2012.48 (2012) (Epub ahead of print).
   Web of Science ®Google Scholar
• Schouten JP , McElgunnCJ, WaaijerR et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30(12) , e57 (2002).
   PubMed Web of Science ®Google Scholar
• Iafrate AJ , FeukL, RiveraMN et al. Detection of large-scale variation in the human genome. Nat. Genet. 36(9) , 949–951 (2004).
   PubMed Web of Science ®Google Scholar
• Sim SC , Ingelman-SundbergM. The human cytochrome P450 Allele Nomenclature Committee web site: submission criteria, procedures, and objectives. Methods Mol. Biol.320 , 183–191 (2006).
   PubMedGoogle Scholar
• Lupski JR , StankiewiczP. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet.1(6) , e49 (2005).
   PubMed Web of Science ®Google Scholar
• Stuppia L , AntonucciI, PalkaG, GattaV. Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int. J. Mol. Sci.13(3) , 3245–3276 (2012).
   PubMed Web of Science ®Google Scholar

▪ Website

• US FDA, Summary Minutes of the Clinical Pharmacology Subcommittee Meeting of the Advisory Committee for Pharmaceutical Science, Silver Spring, Maryland, USA, 14–15 November 2005. www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4194M1.pdf (Accessed 9January2013)
   Google Scholar

• Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‑year survival: an overview of the randomised trials. Lancet365(9472) , 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan VC . Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat.2(2) , 123–128 (1982).
   PubMedGoogle Scholar
• Johnson MD , ZuoH, LeeKH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2) , 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Jin Y , DestaZ, StearnsV et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97(1) , 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Lyon E , GastierFJ, PalomakiGE et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet. Med. 14(12) , 990–1000 (2012).
   PubMed Web of Science ®Google Scholar
• Punglia RS , BursteinHJ, WinerEP, WeeksJC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl Cancer Inst.100(9) , 642–648 (2008).
   PubMedGoogle Scholar
• Forbes JF , CuzickJ, BuzdarA, HowellA, TobiasJS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists‘ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9(1) , 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Thürlimann B , KeshaviahA, CoatesAS et al.; Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26) , 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Mouridsen H , Giobbie-HurderA, GoldhirschA et al.; BIG 1–98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med.361(8) , 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Forbes JF , CuzickJ, BuzdarA et al.; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists‘ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100‑month analysis of the ATAC trial. Lancet Oncol.9(1) , 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Regan MM , Leyland-JonesB, BouzykM, et al.CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J. Natl Cancer Inst.104(6) , 441–451 (2012).
   PubMed Web of Science ®Google Scholar